Expression of isocitrate dehydrogenase-1 in glioblastoma, Bangladesh perspective
DOI:
https://doi.org/10.18203/2320-6012.ijrms20233977Keywords:
IDH1, Glioblastoma, Brain tumorsAbstract
Background: Glioblastoma is the most frequent malignant brain tumor in adults. Various studies have identified IDH (isocitrate dehydrogenase) mutation as a hallmark genetic alteration in glial tumors. The World Health Organization (WHO) has classified glioblastoma based on IDH mutation status, including IDH-mutant glioblastoma, IDH-wildtype glioblastoma along with its variants and glioblastoma, NOS (not otherwise specified) (where IDH mutation status cannot be evaluated).
Methods: It was a cross-sectional observational study, conducted on 35 histologically diagnosed cases of glioblastoma, within the period of March, 2018 to December 2019.
Results: Among the 35 glioblastoma cases, 6 (17.14%) were found to be IDH-mutant (positive for IDH1 immunostain), while the remaining 29 cases were negative for IDH1 immunostain (therefore designated as IDH-wildtype glioblastoma). In the IDH-mutant group, 3 out of 6 patients were in the younger age group (≤40 years). On the other hand, IDH-wildtype glioblastoma was more common in elderly and most frequent was in the age group of 51-60 years (11 out of 29 cases).
Conclusions: In this study, IDH1 expression was observed in 17.14% of all glioblastoma cases (designated as IDH-mutant glioblastoma). Whereas, most (~82.86%) of the glioblastoma cases did not express IDH1 (designated as IDH-wildtype).
References
Cavenee WK, Louis DN, Ohgaki H, Wiestler OD, eds. WHO classification of tumours of the central nervous system. Vol. 1. WHO Regional Office Europe; 2016.
Watanabe T, Nobusawa S, Kleihues P, Ohgaki H. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol. 2009;174(4):1149-53.
Nobusawa S, Watanabe T, Kleihues P, Ohgaki H. IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin Cancer Res. 2009;15(19):6002-7.
Zou Y, Bai HX, Wang Z, Yang L. Comparison of immunohistochemistry and DNA sequencing for the detection of IDH1 mutations in gliomas. Neuro-oncology. 2015;17(3):477-8.
Capper D, Weißert S, Balss J, Habel A, Meyer J, Jäger D, et al. Characterization of R132H mutation‐specific IDH1 antibody binding in brain tumors. Brain Pathol. 2010;20(1):245-54.
Mellai M, Piazzi A, Caldera V, Monzeglio O, Cassoni P, Valente G, et al. IDH1 and IDH2 mutations, immunohistochemistry and associations in a series of brain tumors. J Neuro-Oncol. 2011;105:345-57.
Takano S, Tian W, Matsuda M, Yamamoto T, Ishikawa E, Kaneko MK, et al. Detection of IDH1 mutation in human gliomas: comparison of immunohistochemistry and sequencing. Brain Tumor Pathol. 2011;28:115-23.
Agarwal S, Sharma MC, Jha P, Pathak P, Suri V, Sarkar C, et al. Comparative study of IDH1 mutations in gliomas by immunohistochemistry and DNA sequencing. Neuro-Oncology. 2013;15(6):718-26.
Catteau A, Girardi H, Monville F, Poggionovo C, Carpentier S, Frayssinet V, et al. A new sensitive PCR assay for one-step detection of 12 IDH1/2 mutations in glioma. Acta Neuropathol Commun. 2014;2(1):1-2.
Preusser M, Wöhrer A, Stary S, Höftberger R, Streubel B, Hainfellner JA. Value and limitations of immunohistochemistry and gene sequencing for detection of the IDH1-R132H mutation in diffuse glioma biopsy specimens. J Neuropathol Exp Neurol. 2011;70(8):715-23.
Lee D, Suh YL, Kang SY, Park TI, Jeong JY, Kim SH. IDH1 mutations in oligodendroglial tumors: comparative analysis of direct sequencing, pyrosequencing, immunohistochemistry, nested PCR and PNA‐mediated clamping PCR. Brain Pathol. 2013;23(3):285-93.
Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009;360(8):765-73.
